Advertisement
Singapore markets close in 20 minutes
  • Straits Times Index

    3,274.13
    -13.62 (-0.41%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,108.88
    +30.02 (+0.37%)
     
  • Bitcoin USD

    64,392.95
    +610.38 (+0.96%)
     
  • CMC Crypto 200

    1,389.89
    -6.64 (-0.48%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,358.80
    +16.30 (+0.70%)
     
  • Crude Oil

    83.74
    +0.17 (+0.20%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,574.16
    +4.91 (+0.31%)
     
  • Jakarta Composite Index

    7,056.09
    -99.21 (-1.39%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

FILE PHOTO: French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo (Reuters)

PARIS (Reuters) - French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement. PSA had posted a series of record earnings results over the last two years, having rebounded from a 2012 brush with bankruptcy, and Chasseloup de Chatillon had been a member of Peugeot's managing board since 2012. Chasseloup de Chatillon will arrive at Sanofi at a time of blockbuster deals within the global healthcare industry. Sanofi has already struck two major takeover deals this year, buying haemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros ($4.5 billion). The transactions marked a return to successful deal-making for Sanofi after failures to land major takeovers since 2011, when it bought U.S biotech company Genzyme for around $20 billion, although some investors have questioned the costs. (Reporting by Sudip Kar-Gupta and Gilles Guillaume; Editing by Bate Felix)